Chen, Hongxia Wang, Ning Li, Yin Xie, Xiaohong Yang, Yi
Published in
Frontiers in Oncology
Atypical Chronic Myeloid Leukemia (aCML), a myeloproliferative neoplasm with poor prognosis, was reclassified as aCML by the ICC classification, and as MDS/MPN with neutrophilia by the WHO 2022 classification. Due to the heterogeneity of its clinical features and the lack of unique biomarkers, as well as limited treatment options, aCML currently la...
Cai, Sheng Huang, Ying Lance, Jennie Mao, Hsiaoyin Dunbar, Andrew McNulty, Samantha Druley, Todd Li, Yan Baer, Maria Stock, Wendy
...
Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy, we applied a risk-adapted approach to assess the efficacy of ENA monotherapy for patients aged ≥60 years with newly diagnosed IDH2-mutan...
Zheng, Fang Li, Qianqian Yang, Sisi Zhou, Zhen Zeng, Qingfan Liu, Kaiqi
Published in
Hematology (Amsterdam, Netherlands)
This study aimed to evaluate the efficacy of azacitidine (AZA) combined with danazol (DNZ) and thalidomide (THD) maintenance therapy after intensive chemotherapy (IC) in patients with acute myeloid leukemia (AML). we retrospectively analyzed the clinical data of 11 patients treated with AZA combined with DNZ and THD as maintenance therapy after IC ...
Daver, Naval Vyas, Paresh Kambhampati, Suman Al Malki, Monzr Larson, Richard Asch, Adam Mannis, Gabriel Chai-Ho, Wanxing Tanaka, Tiffany Bradley, Terrence
...
PURPOSE: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with...
Jachiet, Vincent Hadjadj, Jérôme Zhao, Lin-Pierre Chasset, François Fain, Olivier Fenaux, Pierre Mekinian, Arsène
Published in
Bulletin du cancer
Systemic inflammatory or autoimmune diseases (SIAD) are observed in up to a quarter of patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML), with a broad clinical spectrum including asymptomatic biological abnormalities, isolated inflammatory clinical manifestations (recurrent fever, arthralgia, neutrophilic derma...
Kako, Shinichi Kimura, Shun-Ichi Wada, Hidenori Komiya, Yusuke Nakasone, Hideki Sakurai, Masatoshi Kato, Jun Tanaka, Masatsugu Fujii, Eriko Tachibana, Takayoshi
...
Published in
Leukemia research
The optimal bridge strategy at the decision for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is unclear. We performed a prospective observational study in which 110 patients with MDS who were decided to undergo HSCT were enrolled. Among these 110 patients, 77 patients were enrolled in thi...
Alsaadi, Daniah Low, Lyndon Zubairu, Mustafa Clesham, Kevin Rowan, Fiachra
Published in
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Azacitidine (AZA), a demethylating agent, is one of the mainstay treatments for patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) who are ineligible for curative allogeneic stem-cell transplantation and is recommended as first-line treatment in multiple countries. While arthralgia and myalgia have been commonly reporte...
Gu, Christine Richardson, Michelle Kita, Ryosuke Santaguida, Marianne Ali, Kamran Strachan, Debbie Dhar, Anukriti Yam, George Anderson, Wade Anderson, Erica
...
PURPOSE: Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric malignancy with myelodysplastic and myeloproliferative features. Curative treatment is restricted to hematopoietic stem-cell transplantation. Fludarabine combined with cytarabine (FLA) and 5-azacitidine (AZA) monotherapy are commonly used pre-transplant therapies. Here, we ...
Kataoka, Asami Mizumoto, Chisaki Kanda, Junya Iwasaki, Makoto Sakurada, Maki Oka, Tomomi Fujimoto, Masakazu Yamamoto, Yosuke Yamashita, Kohei Nannya, Yasuhito
...
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by UBA1 somatic mutations and is characterized by late-onset systemic autoimmune inflammation and blood abnormalities such as cytopenia, vacuolation of myeloid/erythroblastic cells, and myelodysplastic syndrome (MDS). It is often resistant to immunosuppressive thera...
Yamaoka, Kenta Fujiwara, Masaki Uchida, Mayako Uesawa, Yoshihiro Muroi, Nobuyuki Shimizu, Tadashi
Published in
Oncology
Introduction: Azacitidine is a useful drug for myelodysplastic syndromes and acute myeloid leukemia. In clinical trials, hematologic toxicity and infection have been observed as adverse events (AEs) of this drug. However, information on the time to onset of high risk AEs and subsequent outcomes, as well as differences in the frequency of AEs due to...
